Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids, and improve asthma control and symptoms. How...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2020-09-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/6/3/00068-2020.full |